Study of DLBCL by genetic subtype
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at how different genetic types of diffuse large B-cell lymphoma (DLBCL) respond to treatment in real-world settings. It may help doctors understand which treatments work best for your specific subtype.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of diffuse large B-cell lymphoma (DLBCL).
- Your lymphoma must have a specific genetic subtype (like MCD, BN2, EZB, or others from a gene test).
- You must agree to use reliable birth control if you could become pregnant or get someone pregnant.
- You cannot have severe mental illness that would interfere with the study.
- Your doctor must think you are suitable for the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—pirtobrutinib, lisaftoclax, and rituximab—for people with relapsed or refractory DLBCL who have already had at least one prior treatment. The goal is to see if this combination can help shrink or control the lymphoma.
This study looks at the biology of certain lymphomas to better understand why some people respond well to treatment and others don't. It involves giving a small additional blood or tissue sample to help researchers find genetic clues that could improve future care.
This trial studies whether using a blood test (ctDNA) can help guide treatment decisions for people with newly diagnosed diffuse large B-cell lymphoma. It tests standard chemotherapy regimens (R-CHOP or R-pola-CHP) and aims to improve outcomes by monitoring tumor DNA in the blood.
This study looks at how different factors like age, ethnicity, and other health conditions affect outcomes for people newly diagnosed with a type of blood cancer called diffuse large B-cell lymphoma (DLBCL). It aims to understand inequalities in care and results across the UK.
This study looks at how certain blood tests (like CRP, albumin, and their ratios) might help predict how well treatment works for newly diagnosed DLBCL. If you are getting R-CHOP, this trial could help doctors better understand your response to therapy.
This trial is for people with newly diagnosed DLBCL who have a specific blood marker before treatment and achieve complete remission after standard chemotherapy. The study uses a blood test to help guide whether additional treatment is needed after chemotherapy.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.